Updates

Announcements

Change of Auditor

Dec 24, 2024

ImmuPharma PLC (LSE: IMM), the specialist drug discovery and development company, announces the appointment of Crowe LLP (“Crowe”) as the Company’s new auditor, succeeding CLA Evelyn Partners Limited, with immediate effect. Crowe will conduct the audit of the Company’s financial statements for the financial year ending 31 December 2024 and a proposal to reappoint them…
Appointment of Company Secretary

Dec 4, 2024

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is pleased to confirm the appointment of Ashley Clarke ACA, as Company Secretary to the Company. The appointment is with immediate effect. Ashley has been closely involved with the Company’s accounts for several years via outsourced accountants, providing her with deep familiarity with ImmuPharma’s operations.…
Notification of Major Holding – Lanstead Capital

Oct 11, 2024

To view notification click here
Extension of Warrants in Incanthera to 31 March 2025

Sep 11, 2024

ImmuPharma PLC (LSE: IMM), the specialist drug discovery and development company, is pleased to announce that the Company has agreed with Incanthera plc (“Incanthera”) that Warrants issued to the Company on 26 February 2020, in conjunction with Incanthera’s IPO onto the Aquis Exchange, are extended by a further period to 31 March 2025. Key highlights:…
INTERIM RESULTS for the six months ended 30 June 2024

Sep 9, 2024

ImmuPharma PLC (LSE:IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, is pleased to announce its interim results for the six months ended 30 June 2024 (the “Period”). Key Highlights (including post Period review) Financials Loss for the Period of £0.4m (30 June 2023: £0.8m) Research and development expenses of £0.5m (30…
TR1 – Major Holding – Lanstead

Aug 6, 2024

TR-1: Standard form for notification of major holdings click here
2024 Result of Annual General Meeting – all resolutions passed

Jul 1, 2024

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, held its AGM earlier today. The Company is pleased to announce that all resolutions were duly passed, details of which are contained in the table below. Resolution For % For Against % Against Withheld 1. To receive the accounts of the Company for the year…
Notice of AGM & Annual Report & Accounts

Jun 5, 2024

ImmuPharma PLC (LSE AIM: IMM), the specialist drug discovery and development company, is pleased to confirm that the Company’s Annual General Meeting (“AGM”) will be held on Friday 28 June 2024 @ 11:00a.m. (BST), at the offices of Evelyn Partners, 45 Gresham Street, London, EC2V 7BG. The Notice of AGM setting out details of the…
FINAL RESULTS for the twelve months ended 31 December 2023

Jun 5, 2024

ImmuPharma PLC (LSE:IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, is pleased to announce its Final Results for the twelve months ended 31 December 2023 (the “Period”). Key Highlights (including post Period review) Financials Loss for the Period of £2.9m (2022: £3.8m) Research and development expenses of £2.0m (2022: £2.0m) Administrative expenses of £1.0m (2022: £0.8m)…
Realisation of c£1.5 million on sale of shares in Incanthera plc

Jun 3, 2024

ImmuPharma PLC (LSE AIM: IMM), the specialist drug discovery and development company, announces that it has realised gross proceeds of c£1.5 million on the sale of its entire holding of c9.9 million shares in Incanthera plc. Following this transaction, ImmuPharma retains c7.3 million warrants in Incanthera plc which have an exercise price of 9.5p and…
TR1 – Major Holding – Lanstead

May 3, 2024

To download details click here
IMMUPHARMA at BIO-EQUITY 2024 – 12-14 May 2024, San Sebastian

Apr 24, 2024

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, announces that Tim McCarthy, CEO and Dr Tim Franklin, COO, will be attending BIO-Equity. The event will be held from 12-14 May 2024, in San Sebastian, Spain. BIO-Equity is an annual premier partnering event, designed to provide biotechnology companies with the opportunity to present to…
Grant of Share Options

Apr 19, 2024

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, announces the grant of unapproved share options over ordinary shares of 1 penny each to directors as follows. Lisa Baderoon 3,000,000 share options (exercise price: 2.24p) Laurence Reilly 2,000,000 share options (exercise price: 2.24p) Share Option Period: All Share Options are valid for 10…
New intellectual property strategy initiated to significantly enhance patent life and commercial value for P140 technology platform

Apr 3, 2024

ImmuPharma PLC (LSE AIM: IMM), the specialist drug discovery and development company, is pleased to announce that it has initiated a new intellectual property strategy to significantly enhance the patent life and commercial value for its P140 technology platform. P140 is ImmuPharma’s technology platform for its portfolio in autoimmune diseases. This comprises the lead indication…
Incanthera Provides Commercial Update and Revenue Forecasts

Mar 25, 2024

ImmuPharma PLC (LSE AIM: IMM), the specialist drug discovery and development company, is delighted to highlight the announcement issued this morning by Incanthera plc (“Incanthera”), the dermatology and oncology specialist, in which ImmuPharma currently holds a 10.8% shareholding. Within the announcement, Incanthera announces an update on its commercial skincare deal, announced in December 2023, with…
Grant of Share Options

Mar 19, 2024

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, announces the grant of share options as follows. The Remuneration Committee (comprising the Non-Executive Directors) has determined that the following unapproved Share Options have been awarded to the Executive Directors with vesting conditions which reflect the corporate objective of restoring and enhancing shareholder value as…
IMMUPHARMA AT BIO-EUROPE SPRING 2024. 18-20 March 2024 | Barcelona

Mar 14, 2024

ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, announces that Tim McCarthy, CEO and Dr Tim Franklin, COO, will be attending BIO-Europe Spring. The event will be held between 18-20 March 2024, in Barcelona. BIO-Europe Spring is the premier springtime partnering event, designed to provide biotechnology companies with the opportunity to present to…
Financial, Business and Portfolio Development Update

Mar 6, 2024

ImmuPharma PLC (LSE AIM: IMM), the specialist drug discovery and development company, is pleased to announce a positive and comprehensive financial, business and portfolio development update. This follows on from our announcement on 19 December 2023, where we provided a detailed update on our late stage P140 (Lupuzor™) program, in patients with systemic lupus erythematosus…
TR1 – Major Holding by Lanstead (Date: 28 December 2023)

Jan 2, 2024

To view the form of notification click here
TR1 – Major holding by Lanstead

Dec 20, 2023

To view click here
Simbec-Orion appointed as CRO | Decision to move directly into a Phase 3 pivotal study | Compelling findings on P140’s MOA

Dec 19, 2023

ImmuPharma PLC (LSE AIM: IMM), the specialist drug discovery and development company, is pleased to announce key updates on its late stage P140 (Lupuzor™) program, in patients with systemic lupus erythematosus (“SLE/Lupus”). Highlights Simbec-Orion has been appointed as the Contract Research Organisation (“CRO”), for the P140 (Lupuzor™) Phase 3 study in SLE, following extensive due-diligence…

2025 (21)

2024 (19)

2023 (25)

2022 (27)

2021 (21)

2020 (40)

2019 (19)

2018 (22)

2017 (17)

2016 (25)

2015 (17)

2014 (12)

2011 (2)

Lisa Baderoon

Non-Executive Director and Head of Investor Relations

Lisa has spent over 25 years working within the City of London being involved with a diverse portfolio of clients from a variety of sectors but with a leaning towards emerging, high growth businesses advising both private and public companies on their financial and corporate strategies aligned to stakeholder and investor interests, as well as a strong acumen in media communication. During this time, she has been involved in a multitude of client transactions spanning private fund raisings, Initial Public Offerings (IPOs), secondary high profile capital raisings and mergers and acquisitions both in the UK and internationally.

Lisa had a successful career spanning 20 years as a Partner at Buchanan Communications, one of the leading City financial public relations agencies. As one of the youngest Board members, she was involved in the successful five-year earnout, as part of Buchanan being acquired by the FTSE 100 rated WPP Plc in 1997.

Lisa founded Just B Communications Ltd in 2012 with the key objective of working with a more select number of clients and providing a greater degree of bespoke advisory services thus becoming more integral to the day to day corporate and strategic development for these businesses. She has successfully advised a number of public and private companies, at Board level, on corporate strategy, stakeholder and investor communications, capital raisings, dual listings, licensing and M&A. Media profiling, where required, has also played an important role in advisory activities.

Lisa was appointed Head of Investor Relations at ImmuPharma in 2012 and most recently appointed as a Non-Executive Director in July 2021.

Ketan Patel

Independent Non-Executive Director

Ketan is an experienced investment professional who brings extensive expertise in financial markets, with a particular focus on the UK healthcare and life science sectors. He has been a long-term investor in UK markets, working as both an analyst and Fund Manager, managing institutional, retail, and charity mandates. Ketan began his career at JP Morgan before moving to Insight Investment, where he served as a global Pharmaceutical and Healthcare analyst. He then spent over 20 years at EdenTree Investment Management, where he was responsible for UK equity and global equity income strategies, consistently delivering upper-quartile performance.

Ketan combines rigorous fundamental analysis with risk-focused investment strategies. He is also a published thought leader on sustainability and investment themes. Ketan is a CFA Charterholder and holds an MSc in Economic History from the London School of Economics, an MSc in Geography from King’s College London, and a BA (Hons) in History and Geography from Queen Mary University, London.

Dr Laurence Reilly MBA

Senior Independent Non-Executive Director

Dr Laurence Reilly has been appointed as Senior independent Non-Executive Director and Chair of the Audit Committee. Dr Reilly brings extensive experience in managing late-stage clinical programs through to approval, in addition to commercial and business development experience.

He is currently Vice President of Research & Investments, working with Royalty Pharma, a New York based life science investment company focussing on acquisition of biopharmaceutical royalties and funding of innovation across the biopharmaceutical industry.

Through his consulting practice (Acumen Life Science Investment Consulting) Dr Reilly has provided strategic consulting and due-diligence services to biotech companies, life science venture capital and private equity clients. He also served as Chief Medical Officer for Cellectar Biosciences, New Jersey, a late-stage oncology biotech company. Prior to founding his consulting practice, Dr Reilly served as Chief Scientific Officer and Vice President at Avillion, a drug development company focused on the co-development and financing of drug candidates, where he was responsible for clinical and strategic oversight of co-development programs and partnering with both large pharma and biotech, including Pfizer, Merck KGaA and AstraZeneca. Dr. Reilly previously served as a Clinician – Clinical Development & Medical Oversight at Pfizer and at Lundbeck as Medical & Scientific Advisor.

Dr Reilly earned his medical degree from the University of Liverpool Medical School, U.K., and practiced as Neurosurgery Resident at Queen Elizabeth University Hospital in Birmingham. Dr Reilly also holds a Masters Degree in Law from De Montfort University, U.K.

Dr Tim Franklin PhD, MBA

Chief Operating Officer

Tim has 30 years’ experience in the biopharmaceutical industry. He worked in clinical research, sales & marketing, and global strategic marketing for Warner Lambert, Wellcome and SmithKline Beecham. He later moved to the capital markets where he became a top-ranked pharmaceuticals analyst at Dresdner Kleinwort investment bank. He applied his experience to stock selection at hedge funds and advised several small biotechnology companies on corporate and commercial strategy and access to capital. He holds a BSc in Medicinal Chemistry and a PhD in Pharmacology from Loughborough University and an MBA from Warwick Business School.

Dr Laura Mauran-Ambrosino Ph.D.

Head of R&D

Born in Montpellier, France, Dr Mauran- Ambrosino obtained her PhD in Chemistry at the Université de Bordeaux as a CIFRE fellow in co-supervision by Dr Goudreau.

She then conducted postdoctoral studies at the “Centre Hospitalier Universitaire” Pellegrin in cell biology. In 2018, she joined Ureka and established the biology department and the analytical chemistry department and in 2021, she became Chief Scientific Officer of Ureka Pharma. Dr Mauran-Ambrosino was a key contributor to the development of BioGlucagon, and BioAMB.

Ashley Clarke ACA

Chief Financial Officer & Company Secretary

Ashley brings over a decade of experience in the financial sector. She began her career at a Big Four accounting firm and later advanced her professional expertise by earning her ACA qualification with a respected local firm.

Her professional journey is rooted in auditing, where she developed expertise working with a diverse portfolio of audit and non-audit clients across various industries. Ashley’s experience spans from supporting SMEs to managing large international group consolidations, giving her a comprehensive understanding of financial management across different business scales.

Ashley has been closely involved with the company’s accounts for several years via outsourced accountants, providing her with deep familiarity with its operations. Now, as Group CFO and Company Secretary, she is poised to leverage her extensive knowledge to drive strategic financial growth and ensure robust fiscal management.

Dr Sébastien R. Goudreau Ph.D.

Chief Scientific Officer

Born in Sherbrooke, Québec, Canada, Dr Goudreau obtained his PhD in Chemistry at the Université of Montréal as a NSERC fellow before moving to Switzerland to conduct postdoctoral studies at the ETH Zürich as an FRQNT fellow. He then moved back to Canada for one year where he co-founded FindMolecule inc. and worked for the pharma industry.

In 2014 he joined ImmuPharma as research director and established the research laboratories of Ureka in Bordeaux. After the merger of ELRO with Ureka in 2019, Dr Goudreau became Chief Scientific Officer of Ureka Pharma and in 2021, he became Chief Executive Officer of ImmuPharma Biotech. Notably, Dr Goudreau and his team are credited for the discovery and development of, among others, URK 614, BioGlucagon, and BioAMB.

Tim McCarthy FCCA, MBA

Chief Executive Officer

Tim has 40 years’ international senior level business experience in high growth biotech, healthcare and technology companies. He is also Chairman of Incanthera plc. Tim was formerly Chairman of 4basebio plc and CEO and CFO of a number of UK public listed and private companies including, Alizyme plc and Peptide Therapeutics Group plc, and has a core understanding of AIM and its regulatory processes. Co-founding a number of healthcare and biotechnology companies, he has helped raise substantial amounts of equity capital and also advised and worked at Board level for a diverse range of companies internationally, in areas such as business strategy, mergers & acquisitions, due diligence and licensing.

Announcements

Change of Auditor

Appointment of Company Secretary

Notification of Major Holding – Lanstead Capital

Extension of Warrants in Incanthera to 31 March 2025

INTERIM RESULTS for the six months ended 30 June 2024

TR1 – Major Holding – Lanstead

2024 Result of Annual General Meeting – all resolutions passed

Notice of AGM & Annual Report & Accounts

FINAL RESULTS for the twelve months ended 31 December 2023

Realisation of c£1.5 million on sale of shares in Incanthera plc

TR1 – Major Holding – Lanstead

IMMUPHARMA at BIO-EQUITY 2024 – 12-14 May 2024, San Sebastian

Grant of Share Options

New intellectual property strategy initiated to significantly enhance patent life and commercial value for P140 technology platform

Incanthera Provides Commercial Update and Revenue Forecasts

Grant of Share Options

IMMUPHARMA AT BIO-EUROPE SPRING 2024. 18-20 March 2024 | Barcelona

Financial, Business and Portfolio Development Update

TR1 – Major Holding by Lanstead (Date: 28 December 2023)

TR1 – Major holding by Lanstead

Simbec-Orion appointed as CRO | Decision to move directly into a Phase 3 pivotal study | Compelling findings on P140’s MOA